{"entity":{"type":"insider","cik":"0001668029","url":"/insider/0001668029","json_url":"/insider/0001668029.json","name":"Yu Fan","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":48,"n_filings":14,"first":"2017-04-17","last":"2026-02-05","span_basis":"filed_date"},"name_variants":[{"name":"Yu Fan","source":"filing","n_filings":14,"first_seen":"2017-04-17","last_seen":"2026-02-05"}],"transactions":[{"id":5777556,"accession":"0001493152-26-005410","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-26-005410","line_url":"/filing/0001493152-26-005410#line-1","is_derivative":false,"issuer_cik":"0001374339","issuer_name":"ProMIS Neurosciences Inc.","issuer_ticker":"PMN","issuer_name_source":null,"issuer_url":"/issuer/0001374339","owner_cik":null,"owner_name":"Yu Fan; ABG Management Ltd.; Alex Slanix Paul; Ally Bridge MedAlpha Master Fund L.P.; Ally Bridge Group (NY) LLC","owner_display_name":"Yu Fan","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":700741.0,"shares_display":"700,741","price_per_share":12.13,"price_display":"12.13","price_state":"stated","total_value":8499988.33,"total_display":"8,499,988.33","total_whole":"8,499,988","shares_owned_after":943090.0,"shares_owned_after_display":"943,090","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-05","scope":"insider"},{"id":6532449,"accession":"0000899243-22-014088","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-014088","line_url":"/filing/0000899243-22-014088","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"Ally Bridge MedAlpha Master Fund L.P.; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; ABG WTT-MedAvail Ltd; Yu Fan; Ally Bridge Group (NY) LLC; ABG Management Ltd.; ABG-WTT Global Life Science Capital Partners GP, L.P.; ABG-WTT Global Life Science Capital Partners GP Ltd","owner_display_name":"Ally Bridge MedAlpha Master Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14117646.0,"shares_display":"14,117,646","price_per_share":1.0625,"price_display":"1.06","price_state":"stated","total_value":14999998.875,"total_display":"14,999,998.88","total_whole":"14,999,999","shares_owned_after":15029480.0,"shares_owned_after_display":"15,029,480","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-04-04","filed_date":"2022-04-06","scope":"insider","n_lines":2},{"id":5130608,"accession":"0000899243-21-000379","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-000379","line_url":"/filing/0000899243-21-000379","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"Ally Bridge MedAlpha Master Fund L.P.; ABG-WTT Global Life Science Capital Partners GP, L.P.; Ally Bridge Group (NY) LLC; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; ABG WTT-MedAvail Ltd; Ally Bridge MedAlpha Management L.P.; Ally Bridge MedAlpha Management GP, LLC; Yu Fan; ABG Management Ltd.; ABG-WTT Global Life Science Capital Partners GP Ltd","owner_display_name":"Ally Bridge MedAlpha Master Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12670.0,"shares_display":"12,670","price_per_share":14.9959,"price_display":"15.00","price_state":"stated","total_value":189998.053,"total_display":"189,998.05","total_whole":"189,998","shares_owned_after":3885951.0,"shares_owned_after_display":"3,885,951","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-31","filed_date":"2021-01-05","scope":"insider","n_lines":2},{"id":2462801,"accession":"0000899243-20-035506","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-035506","line_url":"/filing/0000899243-20-035506","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"ABG-WTT Global Life Science Capital Partners GP Ltd; Ally Bridge MedAlpha Management GP, LLC; Yu Fan; ABG-WTT Global Life Science Capital Partners GP, L.P.; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Master Fund L.P.; Ally Bridge Group (NY) LLC; ABG WTT-MedAvail Ltd; ABG Management Ltd.; Ally Bridge MedAlpha Management L.P.","owner_display_name":"ABG-WTT Global Life Science Capital Partners GP Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":1400.0,"total_display":"1,400.00","total_whole":"1,400","shares_owned_after":3879008.0,"shares_owned_after_display":"3,879,008","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-29","filed_date":"2020-12-30","scope":"insider","n_lines":2},{"id":2462789,"accession":"0000899243-20-035506","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-035506","line_url":"/filing/0000899243-20-035506","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"ABG-WTT Global Life Science Capital Partners GP Ltd; Ally Bridge MedAlpha Management GP, LLC; Yu Fan; ABG-WTT Global Life Science Capital Partners GP, L.P.; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Master Fund L.P.; Ally Bridge Group (NY) LLC; ABG WTT-MedAvail Ltd; ABG Management Ltd.; Ally Bridge MedAlpha Management L.P.","owner_display_name":"ABG-WTT Global Life Science Capital Partners GP Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7107.0,"shares_display":"7,107","price_per_share":13.9766,"price_display":"13.98","price_state":"stated","total_value":99331.6962,"total_display":"99,331.70","total_whole":"99,332","shares_owned_after":3878953.0,"shares_owned_after_display":"3,878,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-28","filed_date":"2020-12-30","scope":"insider","n_lines":2},{"id":2133737,"accession":"0000899243-20-035198","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-20-035198","line_url":"/filing/0000899243-20-035198","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"Ally Bridge Group (NY) LLC; Ally Bridge MedAlpha Management L.P.; ABG Management Ltd.; ABG-WTT Global Life Science Capital Partners GP Ltd; ABG-WTT Global Life Science Capital Partners GP, L.P.; Ally Bridge MedAlpha Management GP, LLC; Yu Fan; ABG WTT-MedAvail Ltd; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Master Fund L.P.","owner_display_name":"Ally Bridge Group (NY) LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8890.0,"shares_display":"8,890","price_per_share":13.9919,"price_display":"13.99","price_state":"stated","total_value":124387.991,"total_display":"124,387.99","total_whole":"124,388","shares_owned_after":3875059.0,"shares_owned_after_display":"3,875,059","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-24","filed_date":"2020-12-28","scope":"insider","n_lines":2},{"id":2133729,"accession":"0000899243-20-035198","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-035198","line_url":"/filing/0000899243-20-035198","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"Ally Bridge Group (NY) LLC; Ally Bridge MedAlpha Management L.P.; ABG Management Ltd.; ABG-WTT Global Life Science Capital Partners GP Ltd; ABG-WTT Global Life Science Capital Partners GP, L.P.; Ally Bridge MedAlpha Management GP, LLC; Yu Fan; ABG WTT-MedAvail Ltd; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Master Fund L.P.","owner_display_name":"Ally Bridge Group (NY) LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21700.0,"shares_display":"21,700","price_per_share":13.9865,"price_display":"13.99","price_state":"stated","total_value":303507.05,"total_display":"303,507.05","total_whole":"303,507","shares_owned_after":3870188.0,"shares_owned_after_display":"3,870,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-23","filed_date":"2020-12-28","scope":"insider","n_lines":2},{"id":2133723,"accession":"0000899243-20-035198","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-035198","line_url":"/filing/0000899243-20-035198","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"Ally Bridge Group (NY) LLC; Ally Bridge MedAlpha Management L.P.; ABG Management Ltd.; ABG-WTT Global Life Science Capital Partners GP Ltd; ABG-WTT Global Life Science Capital Partners GP, L.P.; Ally Bridge MedAlpha Management GP, LLC; Yu Fan; ABG WTT-MedAvail Ltd; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Master Fund L.P.","owner_display_name":"Ally Bridge Group (NY) LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16948.0,"shares_display":"16,948","price_per_share":13.7016,"price_display":"13.70","price_state":"stated","total_value":232214.7168,"total_display":"232,214.72","total_whole":"232,215","shares_owned_after":3858298.0,"shares_owned_after_display":"3,858,298","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-22","filed_date":"2020-12-28","scope":"insider","n_lines":2},{"id":3320287,"accession":"0000899243-20-034836","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-034836","line_url":"/filing/0000899243-20-034836","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"ABG Management Ltd.; Ally Bridge MedAlpha Master Fund L.P.; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Management L.P.; Ally Bridge MedAlpha Management GP, LLC; Ally Bridge Group (NY) LLC; ABG-WTT Global Life Science Capital Partners GP, L.P.; Yu Fan; ABG-WTT Global Life Science Capital Partners GP Ltd; ABG WTT-MedAvail Ltd","owner_display_name":"ABG Management Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16277.0,"shares_display":"16,277","price_per_share":13.3147,"price_display":"13.31","price_state":"stated","total_value":216723.3719,"total_display":"216,723.37","total_whole":"216,723","shares_owned_after":3849011.0,"shares_owned_after_display":"3,849,011","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-21","filed_date":"2020-12-22","scope":"insider","n_lines":2},{"id":3320280,"accession":"0000899243-20-034836","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-034836","line_url":"/filing/0000899243-20-034836","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"ABG Management Ltd.; Ally Bridge MedAlpha Master Fund L.P.; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Management L.P.; Ally Bridge MedAlpha Management GP, LLC; Ally Bridge Group (NY) LLC; ABG-WTT Global Life Science Capital Partners GP, L.P.; Yu Fan; ABG-WTT Global Life Science Capital Partners GP Ltd; ABG WTT-MedAvail Ltd","owner_display_name":"ABG Management Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":18600.0,"shares_display":"18,600","price_per_share":13.5946,"price_display":"13.59","price_state":"stated","total_value":252859.56,"total_display":"252,859.56","total_whole":"252,860","shares_owned_after":3840092.0,"shares_owned_after_display":"3,840,092","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-18","filed_date":"2020-12-22","scope":"insider","n_lines":2},{"id":2685424,"accession":"0000899243-20-034482","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-20-034482","line_url":"/filing/0000899243-20-034482","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"Ally Bridge MedAlpha Management L.P.; ABG-WTT Global Life Science Capital Partners GP Ltd; Ally Bridge MedAlpha Management GP, LLC; ABG-WTT Global Life Science Capital Partners GP, L.P.; ABG Management Ltd.; Yu Fan; ABG WTT-MedAvail Ltd; Ally Bridge Group (NY) LLC; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Master Fund L.P.","owner_display_name":"Ally Bridge MedAlpha Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14954.0,"shares_display":"14,954","price_per_share":13.254079691052562,"price_display":"13.25","price_state":"stated","total_value":198201.5077,"total_display":"198,201.51","total_whole":"198,202","shares_owned_after":3828652.0,"shares_owned_after_display":"3,828,652","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-17","filed_date":"2020-12-18","scope":"insider","n_lines":4},{"id":2685408,"accession":"0000899243-20-034482","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-034482","line_url":"/filing/0000899243-20-034482","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"Ally Bridge MedAlpha Management L.P.; ABG-WTT Global Life Science Capital Partners GP Ltd; Ally Bridge MedAlpha Management GP, LLC; ABG-WTT Global Life Science Capital Partners GP, L.P.; ABG Management Ltd.; Yu Fan; ABG WTT-MedAvail Ltd; Ally Bridge Group (NY) LLC; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Master Fund L.P.","owner_display_name":"Ally Bridge MedAlpha Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":28429.0,"shares_display":"28,429","price_per_share":13.0611,"price_display":"13.06","price_state":"stated","total_value":371314.0119,"total_display":"371,314.01","total_whole":"371,314","shares_owned_after":3821706.0,"shares_owned_after_display":"3,821,706","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-16","filed_date":"2020-12-18","scope":"insider","n_lines":2},{"id":3204090,"accession":"0000899243-20-034209","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-20-034209","line_url":"/filing/0000899243-20-034209","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"ABG-WTT Global Life Science Capital Partners GP, L.P.; ABG-WTT Global Life Science Capital Partners GP Ltd; Ally Bridge Group (NY) LLC; Ally Bridge MedAlpha Management L.P.; ABG Management Ltd.; Ally Bridge MedAlpha Master Fund L.P.; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Management GP, LLC; ABG WTT-MedAvail Ltd; Yu Fan","owner_display_name":"ABG-WTT Global Life Science Capital Partners GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":29429.0,"shares_display":"29,429","price_per_share":12.893536474226103,"price_display":"12.89","price_state":"stated","total_value":379443.8849,"total_display":"379,443.88","total_whole":"379,444","shares_owned_after":3806128.0,"shares_owned_after_display":"3,806,128","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-15","filed_date":"2020-12-16","scope":"insider","n_lines":4},{"id":3204079,"accession":"0000899243-20-034209","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-034209","line_url":"/filing/0000899243-20-034209","is_derivative":false,"issuer_cik":"0001402479","issuer_name":"MedAvail Holdings, Inc.","issuer_ticker":"MDVL","issuer_name_source":null,"issuer_url":"/issuer/0001402479","owner_cik":null,"owner_name":"ABG-WTT Global Life Science Capital Partners GP, L.P.; ABG-WTT Global Life Science Capital Partners GP Ltd; Ally Bridge Group (NY) LLC; Ally Bridge MedAlpha Management L.P.; ABG Management Ltd.; Ally Bridge MedAlpha Master Fund L.P.; Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.; Ally Bridge MedAlpha Management GP, LLC; ABG WTT-MedAvail Ltd; Yu Fan","owner_display_name":"ABG-WTT Global Life Science Capital Partners GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14457.0,"shares_display":"14,457","price_per_share":12.2443,"price_display":"12.24","price_state":"stated","total_value":177015.8451,"total_display":"177,015.85","total_whole":"177,016","shares_owned_after":3790002.0,"shares_owned_after_display":"3,790,002","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-14","filed_date":"2020-12-16","scope":"insider","n_lines":2},{"id":6142260,"accession":"0001209191-18-051069","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-051069","line_url":"/filing/0001209191-18-051069","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Yu Fan; Ally Bridge Group Capital Partners II, L.P.; ABG Innovation-SO Ltd; Ally Bridge LB Healthcare Master Fund Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Li Bin; ABG SRNE Ltd; ABG Management Ltd; ABG II-SO Ltd; Ally Bridge LB Management Ltd","owner_display_name":"Yu Fan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":107814.0,"shares_display":"107,814","price_per_share":4.94022272246647,"price_display":"4.94","price_state":"stated","total_value":532625.1726,"total_display":"532,625.17","total_whole":"532,625","shares_owned_after":1013020.0,"shares_owned_after_display":"1,013,020","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-13","filed_date":"2018-09-14","scope":"insider","n_lines":2},{"id":6142257,"accession":"0001209191-18-051069","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-051069","line_url":"/filing/0001209191-18-051069#line-1","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Yu Fan; Ally Bridge Group Capital Partners II, L.P.; ABG Innovation-SO Ltd; Ally Bridge LB Healthcare Master Fund Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Li Bin; ABG SRNE Ltd; ABG Management Ltd; ABG II-SO Ltd; Ally Bridge LB Management Ltd","owner_display_name":"Yu Fan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":189754.0,"shares_display":"189,754","price_per_share":5.0597,"price_display":"5.06","price_state":"stated","total_value":960098.3138,"total_display":"960,098.31","total_whole":"960,098","shares_owned_after":1120834.0,"shares_owned_after_display":"1,120,834","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-12","filed_date":"2018-09-14","scope":"insider"},{"id":6144161,"accession":"0001209191-18-008299","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-008299","line_url":"/filing/0001209191-18-008299#line-2","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Healthcare Master Fund Ltd; ABG Management Ltd; Ally Bridge Group Capital Partners II, L.P.; ABG Innovation-SO Ltd; Li Bin; Ally Bridge LB Management Ltd; ABG II-SO Ltd; Yu Fan; ABG SRNE Ltd","owner_display_name":"Ally Bridge Group Innovation Capital Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":7.1865,"price_display":"7.19","price_state":"stated","total_value":1077975.0,"total_display":"1,077,975.00","total_whole":"1,077,975","shares_owned_after":1328529.0,"shares_owned_after_display":"1,328,529","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-02-07","filed_date":"2018-02-08","scope":"insider"},{"id":6144157,"accession":"0001209191-18-008299","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-008299","line_url":"/filing/0001209191-18-008299#line-1","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Healthcare Master Fund Ltd; ABG Management Ltd; Ally Bridge Group Capital Partners II, L.P.; ABG Innovation-SO Ltd; Li Bin; Ally Bridge LB Management Ltd; ABG II-SO Ltd; Yu Fan; ABG SRNE Ltd","owner_display_name":"Ally Bridge Group Innovation Capital Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":512912.0,"shares_display":"512,912","price_per_share":6.7541,"price_display":"6.75","price_state":"stated","total_value":3464258.9392,"total_display":"3,464,258.94","total_whole":"3,464,259","shares_owned_after":1478529.0,"shares_owned_after_display":"1,478,529","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-02-06","filed_date":"2018-02-08","scope":"insider"},{"id":6419317,"accession":"0001209191-18-008030","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-008030","line_url":"/filing/0001209191-18-008030","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge LB Healthcare Master Fund Ltd; Li Bin; ABG II-SO Ltd; Ally Bridge LB Management Ltd; ABG SRNE Ltd; ABG Innovation-SO Ltd; Ally Bridge Group Capital Partners II, L.P.; Yu Fan; ABG Management Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.","owner_display_name":"Ally Bridge LB Healthcare Master Fund Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":70721.0,"shares_display":"70,721","price_per_share":8.0038,"price_display":"8.00","price_state":"stated","total_value":566036.7398,"total_display":"566,036.74","total_whole":"566,037","shares_owned_after":3041759.0,"shares_owned_after_display":"3,041,759","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-02-05","filed_date":"2018-02-07","scope":"insider","n_lines":3},{"id":6041090,"accession":"0001104659-18-005307","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-18-005307","line_url":"/filing/0001104659-18-005307","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge LB Management Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Healthcare Master Fund Ltd; ABG SRNE Ltd; Li Bin; Yu Fan; ABG Innovation-SO Ltd; Ally Bridge Group Capital Partners II, L.P.; ABG II-SO Ltd; ABG Management Ltd","owner_display_name":"Ally Bridge LB Management Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":235156.0,"shares_display":"235,156","price_per_share":7.6527,"price_display":"7.65","price_state":"stated","total_value":1799578.3212,"total_display":"1,799,578.32","total_whole":"1,799,578","shares_owned_after":3079242.0,"shares_owned_after_display":"3,079,242","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-01-30","filed_date":"2018-01-31","scope":"insider","n_lines":3},{"id":6041080,"accession":"0001104659-18-005307","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-18-005307","line_url":"/filing/0001104659-18-005307","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge LB Management Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Healthcare Master Fund Ltd; ABG SRNE Ltd; Li Bin; Yu Fan; ABG Innovation-SO Ltd; Ally Bridge Group Capital Partners II, L.P.; ABG II-SO Ltd; ABG Management Ltd","owner_display_name":"Ally Bridge LB Management Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":74844.0,"shares_display":"74,844","price_per_share":7.6063,"price_display":"7.61","price_state":"stated","total_value":569285.9172,"total_display":"569,285.92","total_whole":"569,286","shares_owned_after":3203575.0,"shares_owned_after_display":"3,203,575","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-01-29","filed_date":"2018-01-31","scope":"insider","n_lines":3},{"id":4527919,"accession":"0001104659-17-025040","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-17-025040","line_url":"/filing/0001104659-17-025040#line-1","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Yu Fan; Li Bin; ABG SRNE Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Management Ltd; ABG Management Ltd; Ally Bridge LB Healthcare Master Fund Ltd; ABG II-SO Ltd; Ally Bridge Group Capital Partners II, L.P.","owner_display_name":"Yu Fan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":550000.0,"shares_display":"550,000","price_per_share":2.0,"price_display":"2.00","price_state":"stated","total_value":1100000.0,"total_display":"1,100,000.00","total_whole":"1,100,000","shares_owned_after":1991441.0,"shares_owned_after_display":"1,991,441","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-04-19","filed_date":"2017-04-21","scope":"insider"},{"id":5313940,"accession":"0001104659-17-023841","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-17-023841","line_url":"/filing/0001104659-17-023841","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"ABG SRNE Ltd; Ally Bridge LB Healthcare Master Fund Ltd; Li Bin; Ally Bridge Group Capital Partners II, L.P.; Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Management Ltd; ABG II-SO Ltd; ABG Management Ltd; Yu Fan","owner_display_name":"ABG SRNE Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500000.0,"shares_display":"2,500,000","price_per_share":2.0,"price_display":"2.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":1500000.0,"shares_owned_after_display":"1,500,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-04-13","filed_date":"2017-04-17","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001374339","name":"ProMIS Neurosciences Inc.","url":"/issuer/0001374339","role":"Ten percent owner","n_filings":1,"first_seen":"2026-02-05","last_seen":"2026-02-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001402479","name":"MedAvail Holdings, Inc.","url":"/issuer/0001402479","role":"Ten percent owner","n_filings":7,"first_seen":"2020-12-16","last_seen":"2022-04-06"},{"type":"issuer","type_label":"ISSUER","cik":"0000850261","name":"Sorrento Therapeutics, Inc.","url":"/issuer/0000850261","role":"Ten percent owner","n_filings":6,"first_seen":"2017-04-17","last_seen":"2018-09-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001668029","retrieved_at":"2026-08-26T19:20:33+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}